The Innovation | Master: Lin Shen
Research Interests
Her research interest is the oncology of gastrointestinal cancer diagnosis, therapy, and Multi-Disciplinary Team (MDT) therapy, including 1. based on the abundant patients, leading many clinical trials to explore the treatment of advanced gastrointestinal cancers； 2. established the pre-clinical PDX models of advanced gastrointestinal cancers which were widely used in the development of research and new drugs；3. the research based on the molecular subtyping, efficacy prediction markers, and resistance mechanism of gastrointestinal cancers.
Classic Figures
1.The study demonstrated that after surgical removal of primary oesophageal cancers, low-dose adjuvant epigenetic therapy disrupts the premetastatic microenvironment and inhibits both the formation and growth of lung metastases through its selective effect on myeloid-derived suppressor cells (MDSCs). A combination of low-dose adjuvant epigenetic modifiers that disrupts this premetastatic microenvironment and inhibits metastases may permit an adjuvant approach to cancer therapy.
Nature. 2020, 579(7798): 284-290
2. The authors established a simple model of early interdisciplinary supportive care that showed improved survival in patients with metastatic esophagogastric cancer (EGC). This study provides new clinical evidence supporting the early integration of nutritional and psychological supportive care into standard oncologic care for those with metastatic EGC.
J Clin Oncol. 2021, 397(7): 748-756
3. The study demonstrated the dynamic HER2 phenotype on circulating tumor cells (CTC; cHER2) in gastric cancer patients during therapy in both histopathologic HER2+ (hHER2+) and hHER2- patients. Compared with conventional one-time hHER2 examination showing low positivity on primary tumor, more than 70% of patients in both hHER2+ and hHER2- cohorts dynamically acquired cHER2+ phenotype on CTCs. Acquisition of cHER2+ correlated with resistance to the targeted and/or chemotherapy.
Clin Cancer Res. 2018,24(21): 5261-5271.
Selected Publications
1. Zhihao Lu, Jianling Zou, Shuang Li et al., Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020, 579(7798): 284-290.
2. Zhihao Lu, Yu Fang, Chang Liu et al., Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase 3 randomized controlled trial. Journal of Clinical Oncology. J Clin Oncol. 2021，397(7): 748-756.
3. Xu Jianming*, Shen Lin*, Bai Chunmei et al., Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020, 21(11): 1489-1499.
4. Xu Jianming*, Shen Lin*, Zhou Zhiwei et al., Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2020, 21(11): 1500-1512.
5. Sai Ge*, Xia Xia*, Chen Ding* et al., A proteomic landscape of diffuse-type gastric cancer. Nat Commun. 2018, 9(1): 1012-1027.
Website
www.bjcancer.org/Html/Doctors/Main/Index_31049.html
Address
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian District, Beijing, 100142, China
shenlinATbjmu.edu.cn